A safety profile of medications used to treat Waldenström’s macroglobulinemia

References

• Swerdlow SH, Campo E, Pileri SA, et al. The revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. New England J Med. 2012;367(9):826–833.
   PubMed Web of Science ®Google Scholar
• Jimenez C, Sebastian E, Chillon MC, et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom’s macroglobulinemia. Leukemia. 2013;27(8):1722–1728.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Olszewski AJ, Kanan S, et al. Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the surveillance, epidemiology and end results database. Br J Haematol. 2015;169(1):81–89.
   PubMed Web of Science ®Google Scholar
• Garcia-Sanz R, Montoto S, Torrequebrada A, et al. Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol. 2001;115(3):575–582.
   PubMed Web of Science ®Google Scholar
• Phekoo KJ, Jack RH, Davies E, et al. The incidence and survival of Waldenstrom’s macroglobulinaemia in South East England. Leuk Res. 2008;32(1):55–59.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s macroglobulinemia. Semin Oncol. 2003;30(2):116–120.
   PubMed Web of Science ®Google Scholar
• Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenstrom’s Macroglobulinemia. Blood. 2016;128(10):1321–1328.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Owen RG, et al. Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 2014;124(9):1404–1411.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s Macroglobulinemia. J Clin Oncol. 2009;27(1):120–126.
   PubMed Web of Science ®Google Scholar
• Treon SP, Gertz MA, Dimopoulos M, et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom’s Macroglobulinemia. Blood. 2006;107(9):3442–3446.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Anagnostopoulos A, Anderson K, et al. Treatment recommendations in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003;30(2):121–126.
   PubMed Web of Science ®Google Scholar
• Administration. UFaD. FDA expands approved use of Imbruvica for Waldenström’s macroglobulinemia. 2015 Jan 29 [cited 2018 Feb 3]. Available from: https://wwwaccessdatafdagov/drugsatfda_docs/appletter/2015/205552orig1s002ltrpdf
   Google Scholar
• Raedler LA. Imbruvica (Ibrutinib): first drug approved for the treatment of patients with Waldenstrom’s macroglobulinemia. Am Health Drug Benefits. 2016;9(Spec Feature):89–92.
   PubMedGoogle Scholar
• Garcia-Sanz R, Ocio EM. Novel treatment regimens for Waldenstrom’s macroglobulinemia. Expert Rev Hematol. 2010;3(3):339–350.
   PubMed Web of Science ®Google Scholar
• Anagnostopoulos A, Hari PN, Perez WS, et al. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom’s macroglobulinemia. Biol Blood Marrow Transplant. 2006;12(8):845–854.
   PubMed Web of Science ®Google Scholar
• Kyriakou C, Canals C, Sibon D, et al. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28(13):2227–2232.
   PubMed Web of Science ®Google Scholar
• Kyriakou C, Canals C, Cornelissen JJ, et al. Allogeneic stem-cell transplantation in patients with Waldenstrom macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28(33):4926–4934.
   PubMed Web of Science ®Google Scholar
• Cornell RF, Bachanova V, D’Souza A, et al. Allogeneic transplantation for relapsed Waldenstrom macroglobulinemia and lymphoplasmacytic lymphoma. Biol Blood Marrow Transplant. 2017;23(1):60–66.
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstrom’s macroglobulinemia. N Engl J Med. 2015;372(15):1430–1440.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenstrom’s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017;18(2):241–250.
   PubMed Web of Science ®Google Scholar
• Administration EMA. Last accession. 2017 Feb 5. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003791/WC500177775.pdf
   Google Scholar
• Kyle RA, Greipp PR, Gertz MA, et al. Waldenstrom’s macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol. 2000;108(4):737–742.
   PubMed Web of Science ®Google Scholar
• Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013;31(3):301–307.
   PubMed Web of Science ®Google Scholar
• Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009;27(2):250–255.
   PubMed Web of Science ®Google Scholar
• Treon SP, Branagan AR, Hunter Z, et al. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom’s macroglobulinemia. Ann Oncol. 2004;15(10):1481–1483.
   PubMed Web of Science ®Google Scholar
• Tedeschi A, Benevolo G, Varettoni M, et al. Final results of the phase II multicenter Italian study of immunochemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) for symptomatic Waldenstrom’s macroglobulinemia. Haematologica. 2009;94(s2):404a.
   Google Scholar
• Gertz MA, Abonour R, Heffner LT, et al. Clinical value of minor responses after 4 doses of rituximab in Waldenstrom macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. Br J Haematol. 2009;147(5):677–680.
   PubMed Web of Science ®Google Scholar
• Rituximab full prescribing information. 2010. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103705s5311lbl.pdf
   Google Scholar
• Leblond V, Ben-Othman T, Deconinck E, et al. Activity of fludarabine in previously treated Waldenstrom’s macroglobulinemia: a report of 71 cases. Groupe Cooperatif Macroglobulinemiea. J Clin Oncol. 1998;16(6):2060–2064.
   PubMed Web of Science ®Google Scholar
• Thomas SK, Delasalle KB, Gavino M, et al. 2-CDA-cyclophosphamide +/- rituximab for symptomatic WM. Haematologica-The Hematol J. 2007;92(S2):228.
   Google Scholar
• Tedeschi A, Benevolo G, Varettoni M, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer. 2012;118(2):434–443.
   PubMed Web of Science ®Google Scholar
• Souchet L, Levy V, Ouzegdouh M, et al. Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom’s macroglobulinemia. Am J Hematol. 2016;91(8):782–786.
   PubMed Web of Science ®Google Scholar
• Leblond V, Tamburini J, Levy V, et al. Incidence of disease transformation and development of MDS/AML in 165 patients with Waldenstrom’s macroglobulinemia (WM) treated with fludarabine (F)-based regimen in three studies (French Cooperative Group on CLL/WM). ASH Annu Meet Abstr. 2007;110(11):1291.
   Google Scholar
• Buske C, Hoster E, Dreyling M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia. 2009;23(1):153–161.
   PubMed Web of Science ®Google Scholar
• Ioakimidis L, Patterson CJ, Hunter ZR, et al. Comparative outcomes following CP-R, CVP-R and CHOP-R in Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma. 2009;9(1):62–66.
   PubMedGoogle Scholar
• Treon SP, Hunter Z, Branagan AR. CHOP plus rituximab therapy in Waldenstrom’s macroglobulinemia. Clin Lymphoma. 2005;5(4):273–277.
   PubMedGoogle Scholar
• Abonour R, Zhang LA, Rajkumar SV, et al. Phase II pilot study of rituximab + CHOP in patients with newly diagnosed Waldenstrms macroglobulinemia, an Eastren Cooperative Oncology Group Trial (Study E1A02). Blood. 2008;110(S1):3616.
   Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–1210.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007;25(22):3344–3349.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Gavriatopoulou M, Kyrtsonis MC, et al. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study. Blood. 2015;126(11):1392–1394.
   PubMed Web of Science ®Google Scholar
• Buske C, Sadullah S, Kastritis E, et al. Generation of a large observational pan-European data platform for treatment and outcome patterns in patients with Waldenstrom’s macroglobulinemia. Blood. 2015;126(23):2096.
   Web of Science ®Google Scholar
• Verriere B, Gastaud L, Chamorey E, et al. Description of late onset neutropenia in indolent lymphoma patients treated with bendamustine plus rituximab. Hematol Oncol. 2018;36(1):144–149.
   PubMed Web of Science ®Google Scholar
• Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331–1344.
   PubMed Web of Science ®Google Scholar
• Paludo J, Abeykoon JP, Hesse AB, et al. Bendamustine and rituximab versus dexamethasone, rituximab and cyclophosphamide in patients with Waldenstrom macroglobulinemia (WM). Blood. 2016;128(22):2968.
   Web of Science ®Google Scholar
• Cheson BD, Brugger W, Damaj G, et al. Optimal use of bendamustine in hematologic disorders: treatment recommendations from an international consensus panel - an update. Leuk Lymphoma. 2016;57(4):766–782.
   PubMed Web of Science ®Google Scholar
• Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017;14(7):417–433.
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Mitsiades N, Richardson PG, et al. Novel biologically based therapies for Waldenstrom’s macroglobulinemia. Semin Oncol. 2003;30(2):309–312.
   PubMed Web of Science ®Google Scholar
• Leleu X, Eeckhoute J, Jia X, et al. Targeting NF-{kappa}B in Waldenstrom macroglobulinemia. Blood. 2008;111(10):5068–5077.
   PubMed Web of Science ®Google Scholar
• Leleu X, Xu L, Jia X, et al. Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. Blood. 2009;113(3):626–634.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Treatment of relapsed or refractory Waldenstrom’s macroglobulinemia with bortezomib. Haematologica. 2005;90(12):1655–1658.
   PubMed Web of Science ®Google Scholar
• Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol. 2006;24(13):2105–2112.
   PubMed Web of Science ®Google Scholar
• Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom’s macroglobulinemia: results of WMCTG Trial 03–248. Clin Cancer Res. 2007;13(11):3320–3325.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010;28(8):1422–1428.
   PubMed Web of Science ®Google Scholar
• Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05–180. J Clin Oncol. 2009;27(23):3830–3835.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Garcia-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013;122(19):3276–3282.
   PubMed Web of Science ®Google Scholar
• Gavriatopoulou M, Garcia-Sanz R, Kastritis E, et al. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. Blood. 2017;129(4):456–459.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008;26(29):4784–4790.
   PubMed Web of Science ®Google Scholar
• Cooley L, Dendle C, Wolf J, et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies. Intern Med J. 2014;44(12b):1350–1363.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Garcia-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldnestrom’s macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone and rituximab (BDR): a phase II study of the European Myeloma Network. Blood (ASH Annual Meeting Abstracts). 2009;114(22):2886a.
   Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38.
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom’s macroglobulinemia. Blood. 2014;124(4):503–510.
   PubMed Web of Science ®Google Scholar
• Vesole DH, Richter J, Biran N, et al. Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series. Leuk Lymphoma. 2018;59(1):259–261.
   PubMed Web of Science ®Google Scholar
• Waxman AJ, Clasen S, Hwang WT, et al. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol. 2017;4(3):e174519.
   Web of Science ®Google Scholar
• Lopez-Fernandez T, Martin Garcia A, Santaballa Beltran A, et al. Cardio-onco-hematology in clinical practice. Position paper and recommendations. Rev Esp Cardiol (Engl Ed). 2017;70(6):474–486.
   PubMed Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621–1634.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Meid K, Gustine J, et al. Prospective phase ii study of ixazomib, dexamethasone and rituximab in previously untreated patients with Waldenström macroglobulinemia. Blood. 2017;130(Suppl 1):1487.
   PubMedGoogle Scholar
• Yang G, Zhou Y, Liu X, et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia. Blood. 2013;122(7):1222–1232.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437.
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–516.
   PubMed Web of Science ®Google Scholar
• Gustine JN, Meid K, Dubeau T, et al. Ibrutinib discontinuation in Waldenstrom macroglobulinemia: etiologies, outcomes, and IgM rebound. Am J Hematol. 2018;93(4):511–517.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323–332.
   PubMed Web of Science ®Google Scholar
• Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659–667.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Owen R, Brien SM, et al. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in hematologic malignancies. Blood. 2017;130(Suppl 1):4326.
   Google Scholar
• Tam CS, Opat S, Cull G, et al. Twice daily dosing with the highly specific BTK inhibitor, Bgb-3111, achieves complete and continuous BTK occupancy in lymph nodes, and is associated with durable responses in patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Blood. 2016;128(22):642.
   Web of Science ®Google Scholar
• Tam CS, Trotman J, Opat S, et al. High major response rate, including very good partial responses (VGPR), in patients (pts) with Waldenstrom macroglobulinemia (WM) treated with the highly specific BTK inhibitor Bgb-3111: expansion phase results from an ongoing phase I study. Blood. 2016;128(22):1216.
   Web of Science ®Google Scholar
• Holstein SA, McCarthy PL. Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience. Drugs. 2017;77(5):505–520.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Zomas A, Viniou NA, et al. Treatment of Waldenstrom’s macroglobulinemia with thalidomide. J Clin Oncol. 2001;19(16):3596–3601.
   PubMed Web of Science ®Google Scholar
• Coleman M, Leonard J, Lyons L, et al. Treatment of Waldenstrom’s macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Semin Oncol. 2003;30(2):270–274.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Tsatalas C, Zomas A, et al. Treatment of Waldenstrom’s macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Semin Oncol. 2003;30(2):265–269.
   PubMed Web of Science ®Google Scholar
• Treon SP, Soumerai J, Hunter Z, et al. Novel agents in the treatment of Waldenstrom’s macroglobulinemia: update of WMCTG clinical trials. Haematologica. 2008;92(6).
   Google Scholar
• Treon SP, Soumerai JD, Branagan AR, et al. Lenalidomide and rituximab in Waldenstrom’s macroglobulinemia. Clin Cancer Res. 2009;15(1):355–360.
   PubMed Web of Science ®Google Scholar
• Fouquet G, Guidez S, Petillon MO, et al. Lenalidomide is safe and active in Waldenstrom macroglobulinemia. Am J Hematol. 2015;90(11):1055–1059.
   PubMed Web of Science ®Google Scholar
• Owen RG, Hillmen P, Rawstron AC. CD52 expression in Waldenstrom’s macroglobulinemia: implications for alemtuzumab therapy and response assessment. Clin Lymphoma. 2005;5(4):278–281.
   PubMedGoogle Scholar
• Santos DD, Hatjiharissi E, Tournilhac O, et al. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom’s macroglobulinemia and mast cell disorders. Clin Lymphoma Myeloma. 2006;6(6):478–483.
   PubMedGoogle Scholar
• Treon SP, Soumerai JD, Hunter ZR, et al. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood. 2011;118(2):276–281.
   PubMed Web of Science ®Google Scholar
• Blachly JS, Baiocchi RA. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma. Br J Haematol. 2014;167(1):19–32.
   PubMed Web of Science ®Google Scholar
• Sacco A, Roccaro A, Ghobrial IM. Role of dual PI3/Akt and mTOR inhibition in Waldenstrom’s macroglobulinemia. Oncotarget. 2010;1(7):578–582.
   PubMedGoogle Scholar
• Ghobrial IM, Witzig TE, Gertz M, et al. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia. Am J Hematol. 2014;89(3):237–242.
   PubMed Web of Science ®Google Scholar
• Treon SP, Meid K, Tripsas C, et al. Prospective, multicenter clinical trial of everolimus as primary therapy in Waldenstrom macroglobulinemia (WMCTG 09–214). Clin Cancer Res. 2017;23(10):2400–2404.
   PubMed Web of Science ®Google Scholar
• Leleu X, Jia X, Runnels J, et al. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2007;110(13):4417–4426.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Roccaro A, Hong F, et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom’s macroglobulinemia. Clin Cancer Res. 2010;16(3):1033–1041.
   PubMed Web of Science ®Google Scholar
• Moreau AS, Jia X, Ngo HT, et al. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood. 2007;109(11):4964–4972.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Moreau P, Harris B, et al. A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia. Clin Cancer Res. 2012;18(18):5043–5050.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhou Y, Xu L, et al. PI3K/AKT pathway is activated by MYD88 L265P and use of PI3K-Delta inhibitors induces robust tumor cell killing in Waldenstrom’s macroglobulinemia. Blood. 2013;122(21):4255.
   Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–1018.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014;123(22):3406–3413.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Gustine JN, Meid K, et al. Idelalisib in Waldenstrom macroglobulinemia: high incidence of hepatotoxicity. Leuk Lymphoma. 2017;58(4):1002–1004.
   PubMed Web of Science ®Google Scholar
• Kyriakou C, Boumendil A, Finel H, et al. Autologous stem cell transplantation (ASCT) for the treatment of patients with Waldenstrom’s macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL). A risk factor analysis by the European Society for Blood and Marrow Transplantation (EBMT) Lymphoma Working Party. Blood. 2014;124(21):678.
   PubMed Web of Science ®Google Scholar
• Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom’s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(12):1570–1575.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom macroglobulinemia. Am J Hematol. 2010;85(9):670–674.
   PubMed Web of Science ®Google Scholar